by Mr Christopher Peters, sponsored by BREACH, MedCity and Catapult
Less than 1% of proposed Biomarkers achieve clinical adoption and there is a wide gulf between those published in academic journals and those being translated onto scalable platforms that can be integrated into healthcare systems.
Earlier consideration of Biomarker platform should improve the efficiency and robustness of the research and enhance the likelihood of the end product being clinically useful. This therefore creates an argument for industry and academia to link up earlier to improve the quality of Biomarker research and ultimately improve success rates.
We believe that there are large number of platforms out there being developed by small to large companies which would be an excellent match for many Biomarker projects. The difficulty is how to link together the academics and these companies to see where goals and needs align.
A matchmaking event where Biomarker academics from across London will present a short description of their research interests. This will be followed by short pitches from technology companies covering their platforms or services.
After the presentation there is an opportunity to link together researchers and industry representatives who could work together on current or future projects.